Access to anti-retroviral drugs, female in Luxembourg

Luxembourg: Access to anti-retroviral drugs, female was 87.0% in 2024. ▲ Rising

Latest (2024)
87.0%
Change on year
up 1.2%
World rank
45th
of 141 countries
All-time high
87.0%
in 2024
All-time low
35.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, female in Luxembourg, 2000–2024

0204060802000201220242000: 35 %2001: 35 %2002: 39 %2003: 38 %2004: 41 %2005: 49 %2006: 50 %2007: 47 %2008: 48 %2009: 51 %2010: 53 %2011: 55 %2012: 60 %2013: 59 %2014: 64 %2015: 68 %2016: 69 %2017: 70 %2018: 71 %2019: 72 %2020: 72 %2021: 73 %2022: 83 %2023: 86 %2024: 87 %

Source: UNAIDS estimates. Measured in %.

Analysis

Luxembourg recorded 87.0% for access to anti-retroviral drugs, female in 2024. That is the highest value across all 25 years on record.

The figure is up 1.2% on the previous year and up 35.9% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Luxembourg peaked at 87.0% in 2024 and was at its lowest, 35.0%, in 2000.

Luxembourg ranks 45th of 141 countries on this measure, in the middle of the range.

The long-run direction has been consistently rising across the 25 years of available data.

Access to anti-retroviral drugs, female in Luxembourg, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Luxembourg, 2000 to 2024.
Year % Change
2000 35.0%
2001 35.0% +0.0%
2002 39.0% +11.4%
2003 38.0% -2.6%
2004 41.0% +7.9%
2005 49.0% +19.5%
2006 50.0% +2.0%
2007 47.0% -6.0%
2008 48.0% +2.1%
2009 51.0% +6.2%
2010 53.0% +3.9%
2011 55.0% +3.8%
2012 60.0% +9.1%
2013 59.0% -1.7%
2014 64.0% +8.5%
2015 68.0% +6.2%
2016 69.0% +1.5%
2017 70.0% +1.4%
2018 71.0% +1.4%
2019 72.0% +1.4%
2020 72.0% +0.0%
2021 73.0% +1.4%
2022 83.0% +13.7%
2023 86.0% +3.6%
2024 87.0% +1.2%

Averages by decade

DecadeAverage LowestHighest Years
2000s 43.3% 35.0% 51.0% 10
2010s 64.1% 53.0% 72.0% 10
2020s 80.2% 72.0% 87.0% 5

Countries ranked near Luxembourg

  1. 44 Uganda 88.0% compare
  2. 45 Australia 87.0% compare
  3. 47 Iceland 86.0% compare
  4. 47 Peru 86.0% compare

See the full ranking of 160 places →

More gender data for Luxembourg

All data for Luxembourg →

Frequently asked questions

What is access to anti-retroviral drugs, female in Luxembourg?
Access to anti-retroviral drugs, female in Luxembourg was 87.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Luxembourg?
The highest recorded value was 87.0% in 2024.
What is the lowest access to anti-retroviral drugs, female recorded in Luxembourg?
The lowest recorded value was 35.0% in 2000.
How does Luxembourg rank for access to anti-retroviral drugs, female?
Luxembourg ranks 45th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, female rising or falling in Luxembourg?
Over the last ten years it is up 35.9%. The long-run trend across the full record is rising.
Where does this Luxembourg data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Luxembourg. Statizoid, drawing on UNAIDS estimates. Retrieved 10 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/luxembourg/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/luxembourg/">Access to anti-retroviral drugs, female in Luxembourg</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.